,
Coretag

Coming – January 15

A Groundbreaking Platform For Hard To Treat Cancers

Date and Time

January 15

–

12:00 PM ET / 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

Coretag is developing a new class of cancer medicines designed to reach some of the most difficult areas of solid tumors.

All cancerous tumors contain “dead zones” known as a necrotic core where cancer cells multiply and cause metastasis. These areas are common in fast-growing cancers, hold hidden cells that cause recurrence, and are inaccessible to existing therapies.

Coretag has built a patented Tumor Necrosis Targeting Platform (TNTP) based on the discovery of a unique family of small molecules that specifically bind to necrotic cells.

Coretag allows physicians to image the tumor necrosis and then deliver targeted radiation directly to those areas. This “see it, then treat it” strategy is designed to improve precision while limiting damage to healthy tissue. The company’s lead programs, CyanTag® (diagnostic imaging) and CyanCore® (therapy), have completed key preclinical milestones and are advancing toward first-in-human clinical trials in 2026.

Register today to join our online event with Coretag CEO & Chief Medical Officer, Setareh Shamsili , MD, PhD, to hear how the company is developing a tumor-agnostic therapy platform that can be used across many solid cancers including Breast, Lung, Pancreatic, Prostate and more.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.